Jorge Fernández-Fradejas

6PUBLICATIONS
20CO-AUTHORS
Immunogenetics (incl. genetic immunology)PharmacogenomicsEpidemiological modellingMedical bacteriologyCardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 14, 2026
Immune checkpoint inhibitors for the treatment of cancer in people living with HIV.

Sara Rodríguez-Tierno, Jorge Fernández-Fradejas, Manuel Vélez-Díaz-Pallarés

|Mar 07, 2024
Deprescribing in older patients with advanced cancer referred to palliative care.

Jorge Fernández-Fradejas, Hilario Martínez-Barros, Lourdes Rexach-Cano

|Jan 23, 2024
Potentially inappropriate prescriptions and potential prescription omissions in older people living with HIV.

Jorge Fernández-Fradejas, Eva Delgado-Silveira, Elena González-Burgos

|Jun 20, 2023
Real-world effectiveness and factors associated with increased mortality in non-critically ill patients with COVID-19 pneumonia receiving remdesivir.

Lucía Quesada Muñoz, Jorge Fernández-Fradejas, Hilario Martinez-Barros

|Apr 11, 2022
Fidaxomicin monotherapy versus standard therapy combined with bezlotoxumab for treating patients with Clostridioides difficile infection at high risk of recurrence: a matched cohort study.

Rosa Escudero-Sanchez, Alfonso Muriel García, Sergio García Fernández

|Dec 30, 2020
Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection.

Rosa Escudero-Sánchez, María Ruíz-Ruizgómez, Jorge Fernández-Fradejas

Pageof 1